Search

Displaying results 9931 - 9940 of 10000 in total
  1. Drug

    Ansornitinib

    go.drugbank.com/drugs/DB21577
    Experimental

    The usage of the INN stem '-tinib' in the name indicates that Ansornitinib is a tyrosine kinase inhibitor. Ansornitinib has a monoisotopic molecular weight of 540.25 Da.

  2. Drug

    Garsorasib

    go.drugbank.com/drugs/DB21581
    Investigational

    The usage of the INN stem '-rasib' in the name indicates that Garsorasib is a Ras protein inhibitor. Garsorasib has a monoisotopic molecular weight of 598.26 Da.

  3. Drug

    Gumelutamide

    go.drugbank.com/drugs/DB21615
    Experimental

    The usage of the INN stem '-lutamide' in the name indicates that Gumelutamide is a non-steroid antiandrogen. Gumelutamide has a monoisotopic molecular weight of 420.15 Da.

  4. Drug

    Frevecitinib

    go.drugbank.com/drugs/DB21681
    Investigational

    The usage of the INN stem '-citinib' in the name indicates that Frevecitinib is a Janus kinase inhibitor. Frevecitinib has a monoisotopic molecular weight of 415.18 Da.

  5. Drug

    Odentegravir

    go.drugbank.com/drugs/DB21708
    Experimental

    The usage of the INN stem '-tegravir' in the name indicates that Odentegravir is a HIV integrase inhibitor. Odentegravir has a monoisotopic molecular weight of 421.12 Da.

  6. Drug

    IMMU-114

    go.drugbank.com/drugs/DB18458
    Investigational

    IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.

  7. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.

  8. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]

  9. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  10. Drug

    NOP-1A

    go.drugbank.com/drugs/DB15208
    Investigational

    NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).